GSK shares jump 6% as firm raises sales target, boosts dividends

3 days ago  · GSK shares jumped 5.9% as it lifted its 2031 sales target to over £40 billion. The company plans a £2 billion share buyback over the next 18 months. GSK reported that its total …


Install CouponFollow Chrome Extension   CouponFollow Extension

6%
OFF

GSK Shares Jump 6% As Firm Raises Sales Target, Boosts Dividends

2 weeks from now

3 days ago  · GSK shares jumped 5.9% as it lifted its 2031 sales target to over £40 billion. The company plans a £2 billion share buyback over the next 18 months. GSK reported that its total …

invezz.com

6%
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...

2 weeks from now

3 days ago  · GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion …

reuters.com

6%
OFF

GSK Shares Surge Around 6% As Drugmaker Raises Sales Target And …

2 weeks from now

3 days ago  · Invezz.com - Shares of British pharmaceutical giant GSK (LON: GSK) surged on Wednesday after the company raised its long-term sales forecast and reported strong financial …

investing.com

£2
OFF

GSK Launches £2bn Buyback On Strong HIV And Cancer Drugs Sales

2 weeks from now

3 days ago  · GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as …

ft.com

$2
OFF

GSK Stock Jumps On Long-Term Outlook Boost, $2.5B Share …

2 weeks from now

3 days ago  · GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of …

investopedia.com

7%
OFF

GSK Lifts Long-Term Outlook On Drug Pipeline, Buys Back Shares

2 weeks from now

3 days ago  · The British drugmaker boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected. ... GSK’s shares rose as much as 6.7% in …

yahoo.com

6%
OFF

GSK Boosts Long-term Sales Target As 2024 Revenue Beats …

2 weeks from now

3 days ago  · General Medicines sales climbed 6%, with sales of chronic obstructive pulmonary disease drug Trelegy up 27%. For 2025, GSK expects top-line growth between 3% and 5% at …

marketscreener.com

$2
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago  · GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that …

morningstar.com

6%
OFF

GSK Shares Rise On Upbeat Outlook; Raises 2031 Sales Target

2 weeks from now

3 days ago  · GSK shares were up nearly 6% in London on Wednesday midday amid an upwardly revised long-term sales target on the back of outstanding progress in its late-stage pipeline …

marketscreener.com

6%
OFF

Why GSK Stock Rocketed Nearly 6% Skyward On Wednesday

2 weeks from now

Oct 9, 2024  · Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclips Why GSK Stock Rocketed …

nasdaq.com

5%
OFF

GSK Shares Jump On $2.2 Billion Zantac Settlement - Yahoo Finance

2 weeks from now

Oct 10, 2024  · (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued …

yahoo.com

5%
OFF

GSK Shares Jump On $2.2 Billion Zantac Settlement - Yahoo …

2 weeks from now

Oct 10, 2024  · (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued …

yahoo.com

3%
OFF

GSK Shares Gain On Analyst Upgrade, Price Target Boost

2 weeks from now

Jan 4, 2024  · The GlaxoSmithKline share price forecast of 1,569.13p implies 3.3% upside potential from current levels. GSK shares have gained 9.2% in the past year. GSK shares …

businessinsider.com

6%
OFF

GSK Shares Surge Around 6% As Drugmaker Raises Sales Target And …

2 weeks from now

3 days ago  · Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The …

kalkinemedia.com

FAQs about GSK shares jump 6% as firm raises sales target, boosts dividends Coupon?

Why do GSK shares surge?

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan. ...

What happened to GSK shares in 2031?

GSK shares jumped 5.9% as it lifted its 2031 sales target to over £40 billion. The company plans a £2 billion share buyback over the next 18 months. GSK reported that its total sales grew by 3% in 2024, reaching £31.4 billion. Follow Invezz on Telegram, Twitter, and Google News for instant updates > ...

Will GSK buy back £2 billion?

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. Most Read from Bloomberg The British drugmaker boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected. ...

Why did GSK shares jump 6% on Thursday?

(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer. The deal, announced on Wednesday, was far lower than many analysts and investors had expected, including JP Morgan's projection of $3.5 billion. ...

Why did GSK stock rise so much in London?

GSK’s shares rose as much as 6.7% in London, the most on an intraday basis since October. They’ve been held back by concern over the pipeline and what is seen as few near-term catalysts, down 17% over the past 12 months through Tuesday’s close. The better-than-expected earnings were offset by concern over vaccine sales. ...

What happened to GSK's earnings per share?

Core earnings per share rose 10 per cent year on year to 159.3p, at constant exchange rates, higher than the average analyst estimate for 156.7p. But total earnings per share fell 40 per cent to 63.2p, on a constant currency basis, because GSK agreed to settle litigation over Zantac, a heartburn medication, at a cost of £1.8bn. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension